Purdue In The Lead To Bring Abuse-Deterrent Hydrocodone To Market
This article was originally published in The Pink Sheet Daily
Executive Summary
The privately held specialty pharma released positive Phase III data on an abuse-deterrent extended-release hydrocodone formula, which, if approved, could put Zogenix’s Zohydro in jeopardy.
You may also be interested in...
OxyContin’s Abuse-Deterrent Claims Strong, But Stronger Claims Possible
FDA reviewed all the categories of pre-marketing and post-marketing data outlined by guidance for abuse-deterrent opioids, but only in vitro and liking studies made it into the updated label.
FDA’s Opioid Guidance: Industry Celebrates Multi-Tiered Labeling Cake
Endo says label differentiation in the guidance is a positive step; Commissioner Hamburg tells Congress that if new opioid formulations “significantly” deter abuse, generic versions will have to as well.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.